Live data · NADAC + Part D CY24 · reviewed daily

Adalimumab-Adaz (Adalimumab)

Tumor Necrosis Factor Blocker class · 0 generic manufacturers · 0 ANDAs filed at FDA.

First FDA approval2023-07-01
Generic availableNo (brand-only)
Shortage statusDiscontinued
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$32.5M in CY2024 Part D spend12K claims · 4K beneficiaries · 329 plans surveyed

Lowest NADAC
$1587.82/unit
1 NDCs benchmarked, lowest of all strengths.
Average NADAC
$1587.82
Across all dosage forms in distribution.
Highest NADAC
$1587.82
Range is tight.
Plans with PA
54 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema9 entries indexed · 4 visible
What is Adalimumab-Adaz used for?

Adalimumab-Adaz is tracked in Medicare Part D. Specific indication information is not available in our current dataset.

Is there a generic for Adalimumab-Adaz?

No. Adalimumab-Adaz is brand-only with no generic equivalents currently in market.

How much does my plan pay for Adalimumab-Adaz?

Across 329 Part D plans, Adalimumab-Adaz averages $1587.82/unit (NADAC). Lowest available: $1587.82/unit. Highest in distribution: $1587.82/unit.

Is Adalimumab-Adaz on the FDA shortage list?

Adalimumab-Adaz has been discontinued by its manufacturer(s).

5 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh15 Oct 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file (1 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.